Diagnostic Products Corporation Announces Record Date and Shareholder Meeting Date
07 June 2006 - 10:00PM
Business Wire
Diagnostic Products Corporation (NYSE:DP) announced today that it
has established a record date for a special meeting of its
shareholders to consider and vote upon the proposal to approve the
Agreement and Plan of Merger, dated as of April 26, 2006, by and
among Siemens Medical Solutions USA, Inc., Dresden Acquisition
Corporation (a wholly owned subsidiary of Siemens Medical Solutions
USA) and DPC. DPC shareholders of record at the close of business
on Monday, June 19, 2006 will be entitled to notice of, and to vote
at, the special meeting, which will be held at 10:00 a.m. local
time on Thursday, July 27, 2006 at 5210 Pacific Concourse Drive,
Los Angeles, California. A definitive proxy statement containing
information about the special meeting and the proposed merger will
be filed with the Securities and Exchange Commission and a copy of
the definitive proxy statement, along with other voting materials
and instructions, will be mailed to each shareholder of record as
of the record date. Shareholders are encouraged to read the
definitive proxy statement when it becomes available as it contains
important information about the transaction. About Diagnostic
Products Corporation Diagnostic Products Corporation, founded in
1971, is a leader in the global in vitro diagnostics market. DPC's
product offering includes the widely accepted IMMULITE(R) series of
immunoassay systems, more than 75 immunoassays and an expanding
menu of essential specific allergens and allergy panels that are
run just like other immunoassays. DPC also designs and manufactures
automated laboratory instrumentation and automation solutions that
provide fast, accurate results while enabling its customers to do
"more with less" in a leaner laboratory. DPC addresses the clinical
chemistry and laboratory automation needs of its customers through
partnerships with manufacturers of chemistry systems and reagents.
DPC's combined chemistry and immunoassay menu is one of the largest
and most diversified available, covering most laboratory tests
requested. In fiscal 2005 (December 31), DPC reported sales of $481
million and operating income of $96 million. Additional information
can be found at DPC's website at www.dpcweb.com. DPC has filed a
preliminary proxy statement and will file a definitive proxy
statement and other documents regarding the proposed merger
described in this communication with the Securities and Exchange
Commission. Shareholders are urged to read the definitive proxy
statement when it becomes available, because it will contain
important information about the transaction. A copy of the
definitive proxy statement, along with other voting materials and
instructions, will be mailed to each shareholder of record as of
the record date. Investors and shareholders may obtain a free copy
of the definitive proxy statement (when available) and other
documents filed by DPC with the SEC at the SEC's website at
www.sec.gov. The definitive proxy statement and other relevant
documents may also be obtained free of cost by directing a request
to DPC, 5210 Pacific Concourse Drive, Los Angeles, California
90045, attention: Investor Relations (telephone 310-645-8200). DPC
and its directors and executive officers may be deemed to be
participants in the solicitation of proxies from the shareholders
of DPC in connection with the merger. Information about DPC and its
directors and executive officers can be found in DPC's Proxy
Statements and Annual Reports on Form 10-K filed with the SEC.
Additional information regarding the interests of those persons in
the proposed merger may be obtained by reading the proxy statement
when it becomes available. Except for the historical information
contained herein, this press release contains forward-looking
statements that involve risks and uncertainties that could cause
actual results to differ materially. These factors include
governmental or other action relating to DPC's Chinese affiliate;
the rate of customer demand for DPC's products; DPC's ability to
successfully market new and existing products; its dependence on
certain suppliers; domestic and foreign government regulation; its
ability to keep abreast of technological innovations and to
translate them into new products; competition; political and
economic instability in certain markets including the movements of
foreign currencies relative to the dollar; and other risks and
uncertainties disclosed from time to time in DPC's SEC reports and
filings.
Diagnostic Products (NYSE:DP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Diagnostic Products (NYSE:DP)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Diagnostic Products (New York Stock Exchange): 0 recent articles
More Diagnostic Products Corporation News Articles